AnaptysBio Financial Statements From 2010 to 2026

ANAB Stock  USD 43.91  0.71  1.64%   
AnaptysBio's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing AnaptysBio's valuation are provided below:
Gross Profit
16.5 M
Profit Margin
(0.50)
Market Capitalization
1.2 B
Enterprise Value Revenue
5.9613
Revenue
169.5 M
We have found one hundred twenty available fundamental signals for AnaptysBio, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of AnaptysBio prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road.

AnaptysBio Total Revenue

110.22 Million

Check AnaptysBio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AnaptysBio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.9 M, Interest Expense of 60.5 M or Selling General Administrative of 51.2 M, as well as many indicators such as Price To Sales Ratio of 4.5, Dividend Yield of 0.0 or PTB Ratio of 5.79. AnaptysBio financial statements analysis is a perfect complement when working with AnaptysBio Valuation or Volatility modules.
  
Build AI portfolio with AnaptysBio Stock
Check out the analysis of AnaptysBio Correlation against competitors.
For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.

AnaptysBio Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets369.2 M556.4 M292 M
Slightly volatile
Short and Long Term Debt Total446.1 M424.9 M79.5 M
Slightly volatile
Other Current Liabilities47.7 M45.4 M14.6 M
Slightly volatile
Total Current Liabilities54.9 M52.2 M20.9 M
Slightly volatile
Total Stockholder Equity77.4 M81.5 M154.1 M
Slightly volatile
Property Plant And Equipment Net19.6 M18.7 M7.4 M
Slightly volatile
Current Deferred Revenue6.5 M11.7 M6.7 M
Slightly volatile
Accounts Payable4.2 M4.6 M3.3 M
Slightly volatile
Cash134.8 M141.5 M103.2 M
Slightly volatile
Non Current Assets Total53.8 M59.8 M41.4 M
Slightly volatile
Non Currrent Assets Other218.9 K230.4 K577.5 K
Very volatile
Cash And Short Term Investments305.9 M443.2 M240.8 M
Slightly volatile
Common Stock Total Equity22.2 K33.4 K21.6 K
Slightly volatile
Common Stock Shares Outstanding20 M32.6 M16.1 M
Slightly volatile
Liabilities And Stockholders Equity369.2 M556.4 M292 M
Slightly volatile
Non Current Liabilities Total443.8 M422.7 M129.5 M
Slightly volatile
Other Current Assets4.1 M6.6 M3.3 M
Slightly volatile
Other Stockholder Equity488.2 M954.3 M400.6 M
Slightly volatile
Total Liabilities498.7 M474.9 M150.1 M
Slightly volatile
Property Plant And Equipment Gross27.6 M26.3 MM
Slightly volatile
Total Current Assets315.3 M496.7 M250.7 M
Slightly volatile
Short Term Debt2.3 M2.2 M1.9 M
Pretty Stable
Common Stock23.7 K34.5 K21.7 K
Slightly volatile
Other Liabilities367.6 M350.1 M126.3 M
Slightly volatile
Other Assets279.7 K294.4 K1.6 M
Very volatile
Long Term Debt534.4 K562.5 K3.3 M
Slightly volatile
Short and Long Term Debt1.2 M1.2 MM
Slightly volatile
Property Plant Equipment1.6 M2.4 M1.4 M
Slightly volatile
Long Term Debt Total534.4 K562.5 K3.3 M
Slightly volatile
Capital Surpluse517.6 M825.5 M389.4 M
Slightly volatile
Short Term Investments256.7 M301.6 M211.5 M
Slightly volatile
Capital Lease Obligations10.4 M18.4 M6.1 M
Slightly volatile
Net Invested Capital60.6 M63.8 M280.9 M
Slightly volatile
Long Term Investments49.3 M31.9 M65.1 M
Slightly volatile
Non Current Liabilities Other426.8 M406.4 M135.6 M
Slightly volatile
Net Working Capital425 M444.4 M331.2 M
Slightly volatile
Capital Stock30.6 K34.5 K28 K
Slightly volatile

AnaptysBio Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization2.9 M2.8 MM
Slightly volatile
Interest Expense60.5 M57.6 M13.1 M
Slightly volatile
Selling General Administrative51.2 M48.7 M18.8 M
Slightly volatile
Total Revenue110.2 M105 M33.4 M
Slightly volatile
Other Operating Expenses249 M237.2 M90.5 M
Slightly volatile
Research Development197.8 M188.4 M72.2 M
Slightly volatile
Cost Of Revenue197.8 M188.4 M71.3 M
Slightly volatile
Total Operating Expenses51.2 M48.7 M19.1 M
Slightly volatile
Interest Income23.9 M22.8 M7.5 M
Slightly volatile
Reconciled Depreciation1.5 M2.8 M958.2 K
Slightly volatile

AnaptysBio Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation41.1 M39.2 M13.6 M
Slightly volatile
Begin Period Cash Flow39.3 M41.4 M85.6 M
Slightly volatile
Depreciation2.9 M2.8 M1.2 M
Slightly volatile
Other Non Cash Items48 M45.7 M11.2 M
Slightly volatile
Capital Expenditures557.9 K411.7 K421.6 K
Slightly volatile
End Period Cash Flow134.8 M141.5 M103.2 M
Slightly volatile
Change Receivables980 K1.1 M1.2 M
Slightly volatile
Cash Flows Other Operating31.6 M30.1 M11.4 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.54.7349.6246
Very volatile
PTB Ratio5.796.1167
Slightly volatile
Days Sales Outstanding15414762.1289
Slightly volatile
Book Value Per Share2.132.256.052
Slightly volatile
Stock Based Compensation To Revenue0.630.340.62
Slightly volatile
Capex To Depreciation0.160.170.6458
Very volatile
PB Ratio5.796.1167
Slightly volatile
EV To Sales7.457.8445.8368
Very volatile
Payables Turnover0.650.6919.1729
Slightly volatile
Sales General And Administrative To Revenue0.40.420.9392
Slightly volatile
Research And Ddevelopement To Revenue1.531.623.4942
Pretty Stable
Capex To Revenue0.00340.00350.0304
Very volatile
Cash Per Share8.712.228.9848
Slightly volatile
Days Payables Outstanding576548187
Slightly volatile
Income Quality1.381.071.2099
Slightly volatile
Current Ratio10.878.5610.9051
Slightly volatile
Tangible Book Value Per Share2.132.256.052
Slightly volatile
Receivables Turnover1.912.0219.9493
Very volatile
Shareholders Equity Per Share2.132.256.052
Slightly volatile
Debt To Equity6.36.02.6423
Pretty Stable
Capex Per Share0.01660.01140.0174
Slightly volatile
Revenue Per Share3.042.891.3666
Slightly volatile
Interest Debt Per Share13.9713.32.9321
Slightly volatile
Debt To Assets0.720.690.2236
Slightly volatile
Graham Number1.231.391.5146
Slightly volatile
Operating Cycle15414762.1289
Slightly volatile
Price Book Value Ratio5.796.1167
Slightly volatile
Days Of Payables Outstanding576548187
Slightly volatile
Ebt Per Ebit1.181.451.0971
Pretty Stable
Company Equity Multiplier4.997.858.7203
Slightly volatile
Long Term Debt To Capitalization0.790.750.5382
Slightly volatile
Total Debt To Capitalization1.010.960.438
Pretty Stable
Debt Equity Ratio6.36.02.6423
Pretty Stable
Quick Ratio10.878.5610.9051
Slightly volatile
Net Income Per E B T1.11.151.0227
Slightly volatile
Cash Ratio2.322.445.458
Pretty Stable
Days Of Sales Outstanding15414762.1289
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.810.90.9934
Slightly volatile
Price To Book Ratio5.796.1167
Slightly volatile
Fixed Asset Turnover6.146.4712.4703
Pretty Stable
Debt Ratio0.720.690.2236
Slightly volatile
Price Sales Ratio4.54.7349.6246
Very volatile
Asset Turnover0.30.220.4657
Slightly volatile
Price Fair Value5.796.1167
Slightly volatile

AnaptysBio Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap79.5 M89.5 M97.6 M
Slightly volatile
Enterprise Value78 M87.8 M95.8 M
Slightly volatile

AnaptysBio Fundamental Market Drivers

AnaptysBio Upcoming Events

6th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About AnaptysBio Financial Statements

AnaptysBio stakeholders use historical fundamental indicators, such as AnaptysBio's revenue or net income, to determine how well the company is positioned to perform in the future. Although AnaptysBio investors may analyze each financial statement separately, they are all interrelated. For example, changes in AnaptysBio's assets and liabilities are reflected in the revenues and expenses on AnaptysBio's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in AnaptysBio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue11.7 M6.5 M
Total Revenue105 M110.2 M
Cost Of Revenue188.4 M197.8 M
Stock Based Compensation To Revenue 0.34  0.63 
Sales General And Administrative To Revenue 0.42  0.40 
Research And Ddevelopement To Revenue 1.62  1.53 
Revenue Per Share 2.89  3.04 
Ebit Per Revenue(1.45)(1.52)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether AnaptysBio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AnaptysBio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anaptysbio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anaptysbio Stock:
Check out the analysis of AnaptysBio Correlation against competitors.
For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.
You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AnaptysBio. If investors know AnaptysBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AnaptysBio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.82)
Revenue Per Share
5.758
Quarterly Revenue Growth
1.543
Return On Assets
(0.04)
Return On Equity
(3.08)
The market value of AnaptysBio is measured differently than its book value, which is the value of AnaptysBio that is recorded on the company's balance sheet. Investors also form their own opinion of AnaptysBio's value that differs from its market value or its book value, called intrinsic value, which is AnaptysBio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AnaptysBio's market value can be influenced by many factors that don't directly affect AnaptysBio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AnaptysBio's value and its price as these two are different measures arrived at by different means. Investors typically determine if AnaptysBio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AnaptysBio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.